Retatrutide is an investigational triple agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
The side effects of Mounjaro and Ozempic are largely similar
Market timing is a futile exercise
Pain at injection site semaglutide is a recognized local adverse reaction affecting approximately 1.2-1.4% of patients using this GLP-1 receptor agonist for type 2 diabetes or weight management
At a glance GLP-1 medications are changing how consumers eat, with appetite suppression, smaller portions and altered taste preferences driving demand for nutrient-dense, high-protein foods Brands can lead through smarter reformulation, offering products fortified with protein, fibre and clean label sweeteners to help consumers stay nourished on fewer calories Improving nutrient density can drive opportunity high-protein, high fibre, portion-controlled foods and beverages align with new consumer priorities for long-term weight and wellness management Innovation spans multiple categories, with bakery, snacks and beverages being ideal platforms for nutrient-dense reformulations that balance functionality, taste and texture Ingredion's portfolio of resistant starches, prebiotic fibres, pulse proteins and low- and no-calorie sweeteners help formulators meet the evolving nutritional needs of consumers on GLP-1 based medications as well as those looking to manage their weight without pharmaceuticals Weight management trends are redefining nutrition and pushing brands to reformulate For food and beverage brands, this shift represents far more than a dietary trend
